Published in Hepatology on December 01, 2004
The Effect of an RBAC Supplement (BRM4) on NAFLD | NCT02568787
Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis (EASYBEinNASH) | NCT03198572
Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat Genet (2007) 13.78
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet (2008) 10.87
Human fatty liver disease: old questions and new insights. Science (2011) 8.03
A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet (2006) 7.89
Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology (2010) 5.35
Lipid-induced insulin resistance: unravelling the mechanism. Lancet (2010) 4.88
Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology (2014) 4.01
A novel adaptive method for the analysis of next-generation sequencing data to detect complex trait associations with rare variants due to gene main effects and interactions. PLoS Genet (2010) 3.78
Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J Clin Invest (2006) 3.75
Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci (2010) 3.72
Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology (2010) 3.60
The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol (2013) 3.51
The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology (2009) 3.48
A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem (2009) 3.41
Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol (2008) 3.33
Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol (2008) 3.23
Heritability of nonalcoholic fatty liver disease. Gastroenterology (2009) 3.17
The role of lipid droplets in metabolic disease in rodents and humans. J Clin Invest (2011) 3.12
Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat: blinded comparison with MR spectroscopy. Radiology (2011) 3.08
Ethnic differences in hepatic steatosis: an insulin resistance paradox? Hepatology (2009) 3.08
Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects. Gut (2008) 3.01
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol (2013) 2.92
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol (2007) 2.90
Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Natl Acad Sci U S A (2006) 2.88
Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. Gastroenterology (2013) 2.82
Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab (2011) 2.75
The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology (2010) 2.75
A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res (2009) 2.75
Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol (2007) 2.71
Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology (2008) 2.70
Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology (2013) 2.64
Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents. J Clin Invest (2008) 2.58
Nonalcoholic fatty liver disease. CMAJ (2005) 2.56
Pathogenesis of non-alcoholic fatty liver disease. QJM (2009) 2.50
Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology (2010) 2.50
Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol (2013) 2.50
Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet (2014) 2.49
Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease. Gastroenterology (2010) 2.45
Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology (2011) 2.44
Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology (2012) 2.44
Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2009) 2.42
Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol (2010) 2.42
Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes (2009) 2.36
A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci U S A (2010) 2.34
The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature (2014) 2.30
Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology (2010) 2.30
Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2010) 2.28
Sugar-sweetened beverage, diet soda, and fatty liver disease in the Framingham Heart Study cohorts. J Hepatol (2015) 2.26
Recent advances in the pathophysiology of nephrolithiasis. Kidney Int (2008) 2.26
Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol (2010) 2.25
Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004. Gastroenterology (2007) 2.22
Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer (2009) 2.19
Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol (2008) 2.17
Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol (2015) 2.11
Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology (2012) 2.10
Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model. J Hepatol (2010) 2.09
Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology (2010) 2.09
Persistent Liver Biochemistry Abnormalities Are More Common in Older Patients and those With Cholestatic Drug Induced Liver Injury. Am J Gastroenterol (2015) 2.08
Declining liver utilization for transplantation in the United States and the impact of donation after cardiac death. Liver Transpl (2013) 2.07
Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol (2010) 2.06
Serum N(1)-Methylnicotinamide Is Associated With Obesity and Diabetes in Chinese. J Clin Endocrinol Metab (2015) 2.06
Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology (2013) 2.03
Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia (2009) 2.03
Body mass index is the most useful predictive factor for the onset of nonalcoholic fatty liver disease: a community-based retrospective longitudinal cohort study. J Gastroenterol (2012) 2.03
Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology (2014) 2.00
Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr (2009) 1.98
Ethnicity and nonalcoholic fatty liver disease. Hepatology (2012) 1.98
Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab (2012) 1.97
Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab (2009) 1.95
Rats selectively bred for low aerobic capacity have reduced hepatic mitochondrial oxidative capacity and susceptibility to hepatic steatosis and injury. J Physiol (2009) 1.95
Interactions between the intestinal microbiome and liver diseases. Gastroenterology (2014) 1.92
Adipose triglyceride lipase is a major hepatic lipase that regulates triacylglycerol turnover and fatty acid signaling and partitioning. Hepatology (2010) 1.84
JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J Biol Chem (2009) 1.82
Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology (2011) 1.80
Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology (2013) 1.78
Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. Am J Gastroenterol (2016) 1.76
Noninvasive Diagnosis of Nonalcoholic Fatty Liver Disease and Quantification of Liver Fat Using a New Quantitative Ultrasound Technique. Clin Gastroenterol Hepatol (2014) 1.75
Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome. J Lipid Res (2010) 1.75
Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. Dig Dis Sci (2011) 1.74
An evolutionary framework for association testing in resequencing studies. PLoS Genet (2010) 1.74
Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J Gastroenterol (2008) 1.73
Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients (2013) 1.73
Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol (2012) 1.70
Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Med (2011) 1.69
Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J Gastroenterol (2009) 1.68
Risk factors for chronic liver disease in Blacks, Mexican Americans, and Whites in the United States: results from NHANES IV, 1999-2004. Am J Gastroenterol (2008) 1.68
Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol (2007) 1.65
Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function. Obesity (Silver Spring) (2008) 1.64
Treatment of non-alcoholic fatty liver disease. Postgrad Med J (2006) 1.63
Adipocyte metabolism and obesity. J Lipid Res (2008) 1.62
Changes in skeletal muscle and organ size after a weight-loss intervention in overweight and obese type 2 diabetic patients. Am J Clin Nutr (2016) 1.61
Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol (2007) 1.61
A functional ABCA1 gene variant is associated with low HDL-cholesterol levels and shows evidence of positive selection in Native Americans. Hum Mol Genet (2010) 1.60
Non-invasive means of measuring hepatic fat content. World J Gastroenterol (2008) 1.60
Retracted Impairment of central leptin-mediated PI3K signaling manifested as hepatic steatosis independent of hyperphagia and obesity. Cell Metab (2011) 1.60
Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol (2007) 1.59
Ultrasonographic quantitative estimation of hepatic steatosis in children With NAFLD. J Pediatr Gastroenterol Nutr (2011) 1.59
Association between specific adipose tissue CD4+ T-cell populations and insulin resistance in obese individuals. Gastroenterology (2013) 1.57
Sex differences in lipid and lipoprotein metabolism: it's not just about sex hormones. J Clin Endocrinol Metab (2011) 1.55
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation (2005) 43.74
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med (2006) 23.83
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 23.07
Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science (2004) 21.65
Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation (2004) 20.67
A common allele on chromosome 9 associated with coronary heart disease. Science (2007) 20.37
The metabolic syndrome. Lancet (2005) 19.47
Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med (2007) 18.78
Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med (2005) 15.18
Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat Genet (2007) 13.78
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet (2005) 12.12
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet (2008) 10.87
The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am J Cardiol (2004) 9.43
Molecular mediators of hepatic steatosis and liver injury. J Clin Invest (2004) 9.40
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab (2004) 8.36
Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc Natl Acad Sci U S A (2006) 8.20
Human fatty liver disease: old questions and new insights. Science (2011) 8.03
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation (2006) 8.01
A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet (2006) 7.89
Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med (2010) 6.84
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol (2004) 6.50
LDL-cholesterol concentrations: a genome-wide association study. Lancet (2008) 6.44
GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5. Nature (2003) 6.40
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med (2007) 6.31
Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c. J Biol Chem (2002) 5.89
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet (2006) 5.67
Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J Clin Invest (2008) 5.05
Adiposity of the heart, revisited. Ann Intern Med (2006) 4.60
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A (2008) 4.57
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A (2005) 4.56
ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol (2002) 4.50
Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest (2003) 4.42
Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA (2005) 4.22
Genetic variants influencing circulating lipid levels and risk of coronary artery disease. Arterioscler Thromb Vasc Biol (2010) 4.08
Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA (2012) 4.04
Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology (2014) 4.01
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94
Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem (2004) 3.93
PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res (2008) 3.92
Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation (2007) 3.88
Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J Clin Invest (2002) 3.85
Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature (2010) 3.77
Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci (2007) 3.59
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest (2006) 3.54
Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc Natl Acad Sci U S A (2004) 3.54
Race and gender differences in C-reactive protein levels. J Am Coll Cardiol (2005) 3.51
The metabolic syndrome. Lancet (2010) 3.47
Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem (2007) 3.45
Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol (2004) 3.43
A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem (2009) 3.41
Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet (2006) 3.38
Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation (2004) 3.35
ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation (2002) 3.29
Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation (2003) 3.22
Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion. Proc Natl Acad Sci U S A (2002) 3.09
Ethnic differences in hepatic steatosis: an insulin resistance paradox? Hepatology (2009) 3.08
Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care (2004) 3.00
Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev (2006) 2.99
Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation (2004) 2.90
LXRs regulate the balance between fat storage and oxidation. Cell Metab (2005) 2.75
Influence of body fat content and distribution on variation in metabolic risk. J Clin Endocrinol Metab (2006) 2.73
Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Genet (2002) 2.71
Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis. J Clin Invest (2004) 2.66
Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad Sci U S A (2012) 2.62
Inflammation, hypertension, and the metabolic syndrome. JAMA (2003) 2.57
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol (2006) 2.57
Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc (2003) 2.56
ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and biliary cholesterol excretion. J Biol Chem (2003) 2.48
Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci U S A (2008) 2.42
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol (2006) 2.41
A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci U S A (2010) 2.34